Bleeding disorders:

Indications for: MULPLETA

Thrombocytopenia in adults with chronic liver disease who are scheduled to undergo a procedure.

Adult Dosage:

Start treatment 8–14 days prior to a procedure. Should undergo procedure within 2–8 days after last dose. Take with or without food. 3mg once daily for 7 days.

Children Dosage:

Not established.

MULPLETA Warnings/Precautions:

Obtain platelet count prior to treatment and not more than 2 days prior to procedure. Increased thrombotic risk with known risk factors (eg, Factor V Leiden, Prothrombin 20210A, Antithrombin deficiency, Protein C or S deficiency). Ongoing or prior thrombosis or absence of hepatopetal blood flow: use only if potential benefit justifies risk. Do not use to normalize platelet counts. Pregnancy: may cause fetal harm. Nursing mothers: not recommended (during and for ≥28 days after last dose).

MULPLETA Classification:

Thrombopoietin receptor agonist.

Adverse Reactions:

Headache; portal vein thrombosis.

Generic Drug Availability:


How Supplied: